KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Change in Receivables (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Change in Receivables data on record, last reported at $51.2 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 56.54% year-over-year to $51.2 million; the TTM value through Dec 2025 reached -$498.1 million, down 189.91%, while the annual FY2025 figure was -$498.1 million, 189.91% down from the prior year.
  • Change in Receivables reached $51.2 million in Q4 2025 per REGN's latest filing, down from $80.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $494.1 million in Q2 2024 and bottomed at -$1.2 billion in Q1 2022.
  • Average Change in Receivables over 5 years is -$15.0 million, with a median of $58.3 million recorded in 2021.
  • Peak YoY movement for Change in Receivables: plummeted 2154.03% in 2022, then skyrocketed 18200.0% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $58.3 million in 2021, then crashed by 476.67% to -$219.6 million in 2022, then soared by 137.66% to $82.7 million in 2023, then skyrocketed by 42.44% to $117.8 million in 2024, then crashed by 56.54% to $51.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $51.2 million in Q4 2025, $80.3 million in Q3 2025, and $28.2 million in Q2 2025.